PhD molecular biologist with expertise in hematology @CincyChildrens. Outside of lab, I am a father, husband, sports coach, and scout leader. Views are my own.
Cincinnati, OH
Joined July 2008
- Tweets255
- Following153
- Followers270
- Likes978
Tim Chlon retweeted
🚨Apparently all NIH Study Sections have been suspended indefinitely.
For those who don’t know, this means there won’t be any review of grants submitted to NIH
Depending on how long this goes on for, this could lead to an interruption in billions in research funding.
Tim Chlon retweeted
Dr. Emily Stepanchick from the Chlon lab (@tchlon) at @CincyChildrens led this study showing that DDX41 haploinsufficiency causes inefficient #hematopoiesis under stress ⚡ and cooperates with p53 mutations to cause hematologic malignancy.
👉 go.nature.com/3W7WR4C
Tim Chlon retweeted
DDX41 mutations ⬇️⬇️
🔹Germline pathogenic variants = relatively common (1/429)
🔹 Increased risk of MDS/AML
🔹Progression more common in somatic DDX41 variants
🔸Responsive to #venetoclax as previously published
#leusm #leukemia #OncoAlert @BloodJournal
doi.org/10.1182/blood.202302… – at Houston, TX
Tim Chlon retweeted
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neop… pubmed.ncbi.nlm.nih.gov/3719… @TalhaBadarMD @DrAlexFerrer @tchlon #DDX41 #MDS @MayoCancerCare @MayoCancerCare – at Minnesota, USA
Tim Chlon retweeted
The Vera & Joseph Dresner Foundation 2023 RFA for new research proposals in MDS for early career and established investigator awards is open. There's still time to submit a letter of intent for the 2023 cycle!
The Vera & Joseph Dresner Fdn has launched the 2023 RFA for new research proposals in MDS for early career and established investigator awards. LOIs due on 3/17.
Apply here: dresnerfoundation.org/mds-re…
Tim Chlon retweeted
The 2023 Dresner Foundation MDS Research Fund is open for applications! Deadline = March 17. Please share with your colleagues. @aamdsif @MDSFoundation @MDSAlliance dresnerfoundation.org/mds-re…
Tim Chlon retweeted
The splicing workshop is back after the pandemic and returning to NYC! @IcahnMountSinai.
Excited to co-organize with @eirinipapapetr1 the next Workshop on Splicing Factor Mutations and RNA biology in cancer here at Sinai. Registration is open (deadline April 3). Looking forward to seeing you in NYC. #RNAbiology #RNA #Splicing #Cancer
Tim Chlon retweeted
The single most efficient investment in biomedical research would be to underwrite a non-profit competitor to Fisher and other laboratory service companies. Lab equipment should not come with a 1000% markup.
Tim Chlon retweeted
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms | Happy to share this review co-authored with @tchlon | increasingly being recognized as most prevalent germline predisposition sx in myeloid malignancy with fav outcome! readcube.com/articles/10.100…
Tim Chlon retweeted
Join the 8th international #BMF hybrid symposium organized by @aamdsif with expert specialists from all over a world. May 19-20, 2022. Register to participate for free: web.cvent.com/event/3cd53d06…
The faculty includes:
Tim Chlon retweeted
Congrats to @dstarczynowski and @tchlon @ChildrensCBDI for publishing important #MDS #bonemarrow findings in @CellStemCell See the study: bit.ly/38wk7zx View the blog: scienceblog.cincinnatichildr…
Tim Chlon retweeted
Regrettably, the @KeystoneSymp on Hematopoiesis (April 3-7, 2020) has been canceled due to the evolving circumstances involving the coronavirus. We apologize for the inconvenience to the speakers and attendees. More information to come from @KeystoneSymp: bit.ly/KShemato20
Tim Chlon retweeted
There is only 1 week left to submit an abstract for the @KeystoneSymp April 3-7 2020 on the latest research in normal and malignant hematopoiesis. Check out the updated meeting info (bit.ly/KShemato20). #KShemato
Tim Chlon retweeted
There is only one week left to apply for @KeystoneSymp Hematopoiesis Meeting Scholarships (deadline Dec. 5): bit.ly/KSassistance.
Not only are KS Scholarships prestigious, but they also provide invaluable networking and career-development opportunities.
